TY - JOUR

T1 - Комплексное исследование биомаркеров болезни Альцuеймера в плазме крови и цереброспинальной жидкости

AU - Лобзин, Владимир Юрьевич

AU - Миночкин, Алесь Константинович

AU - Емелин, Андрей Юрьевич

AU - Коптева, Юлия Павловна

AU - Клиценко, О.А.

AU - Щербак, Сергей Григорьевич

AU - Апалько, С.В.

PY - 2025/5/27

Y1 - 2025/5/27

N2 - Objective. To determine, evaluate, and analyze the diagnostic value of various laboratory biomarkers of Alzheimer’s disease (AD) in blood and cerebrospinal fluid (CSF). Material and methods. The concentrations of 93 potential biomarkers in plasma and CSF were studied in patients with AD at various stages (n=53) and independently in the group at the predementia stage (n=15). Results. Statistically significant correlations of various directions (p≤0.05) were found between the coefficients characterizing the amyloidosis and neurodegeneration (Aβ-42/Aβ-40, phTau181/Aβ-42, phTau181/oTau, oTau/Aβ-42) with markers associated with neuroinflammation, vascular disorders, angiogenesis, neuroimaging changes, and neuropsychological indicators. Previous studies of markers associated with inflammation in CSF in AD patients have shown mixed results, and no markers have been in-troduced into clinical practice so far. Many biomarkers associated with two classical pathogenetic links and other pathophysio-logical processes have been identified. Conclusion. Coefficients reflecting two main pathogenetic processes in CSF of AD patients (Aβ-42/Aβ-40, phTau181/Aβ-42, phTau181/oTau, oTau/Aβ-42) are the most informative for verifying two main links in the disease pathogenesis—amyloidogenesis and neurodegeneration. In the group of patients with amnestic mild cognitive impairment (aMCI), statistically significant relation-ships of cytokines associated with neuroinflammation, growth factors, and complement system protein with coefficients of amy-loidosis and neurodegeneration in CSF, as well as PET, MRI, and neuropsychological tests were shown; therefore, these indicators can also be considered as potential diagnostic biomarkers of early stages and possible predictors of MCI conversion to dementia. Such markers as GFAP, apolipoprotein A1, GDF-15, IFN-γ, IL-5, IL-7, IL-8, IL-10, IL-12p70, IL-13, IL-17, VEGF, and complement C3 should be considered as objects for further research as biomarkers for early diagnosis.

AB - Objective. To determine, evaluate, and analyze the diagnostic value of various laboratory biomarkers of Alzheimer’s disease (AD) in blood and cerebrospinal fluid (CSF). Material and methods. The concentrations of 93 potential biomarkers in plasma and CSF were studied in patients with AD at various stages (n=53) and independently in the group at the predementia stage (n=15). Results. Statistically significant correlations of various directions (p≤0.05) were found between the coefficients characterizing the amyloidosis and neurodegeneration (Aβ-42/Aβ-40, phTau181/Aβ-42, phTau181/oTau, oTau/Aβ-42) with markers associated with neuroinflammation, vascular disorders, angiogenesis, neuroimaging changes, and neuropsychological indicators. Previous studies of markers associated with inflammation in CSF in AD patients have shown mixed results, and no markers have been in-troduced into clinical practice so far. Many biomarkers associated with two classical pathogenetic links and other pathophysio-logical processes have been identified. Conclusion. Coefficients reflecting two main pathogenetic processes in CSF of AD patients (Aβ-42/Aβ-40, phTau181/Aβ-42, phTau181/oTau, oTau/Aβ-42) are the most informative for verifying two main links in the disease pathogenesis—amyloidogenesis and neurodegeneration. In the group of patients with amnestic mild cognitive impairment (aMCI), statistically significant relation-ships of cytokines associated with neuroinflammation, growth factors, and complement system protein with coefficients of amy-loidosis and neurodegeneration in CSF, as well as PET, MRI, and neuropsychological tests were shown; therefore, these indicators can also be considered as potential diagnostic biomarkers of early stages and possible predictors of MCI conversion to dementia. Such markers as GFAP, apolipoprotein A1, GDF-15, IFN-γ, IL-5, IL-7, IL-8, IL-10, IL-12p70, IL-13, IL-17, VEGF, and complement C3 should be considered as objects for further research as biomarkers for early diagnosis.

KW - Alzheimer’s disease

KW - biomarkers

KW - neurodegeneration

KW - neuroinflammation

KW - vascular growth factors

UR - https://www.mendeley.com/catalogue/280012de-93d1-3648-8b84-5648b29ad1b8/

U2 - 10.17116/jnevro202512504243

DO - 10.17116/jnevro202512504243

M3 - статья

VL - 125

SP - 43

EP - 53

JO - ЖУРНАЛ НЕВРОЛОГИИ И ПСИХИАТРИИ ИМ. C.C. КОРСАКОВА

JF - ЖУРНАЛ НЕВРОЛОГИИ И ПСИХИАТРИИ ИМ. C.C. КОРСАКОВА

SN - 1997-7298

IS - 4-2

ER -